跳至主要内容
临床试验/JPRN-jRCTs031180080
JPRN-jRCTs031180080已完成未知

Study of ifenprodil effects on patients with methamphetamine dependence and development of fMRI biomarkers for methamphetamine dependence - Study of ifenprodil in methamphetamine dependence

Matsumoto Toshihiko0 个研究点目标入组 35 人开始时间: 2019年1月15日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
35

研究概览

简要总结

We examined the safety and appropriate outcomes of ifenprodil for the treatment of patients with methamphetamine dependence. We found that there were no safety issues and a 120 mg/day ifenprodil group improved their drug use status and sub-scale scores on the relapse risk scale compared with placebo and 60 mg/day ifenprodil groups. These results demonstrate the potential that appropriate outcomes can be achieved with high dose ifenprodil treatment for methamphetamine dependence.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1) Outpatients who were diagnosed with methamphetamine use disorder assessed by DSM-5 (including first visit and return visit).
  • 2) Those who used methamphetamine in the past year.
  • 3) Those who are age 20 years old <= at obtaining of informed consent.

排除标准

  • 1) Patients with severe physical diseases.
  • 2) Patients with high suicide risk.
  • 3) Patients with severe symptoms of substance-induced psychotic disorder.
  • 4) Patients with impaired cognitive function.
  • 5) Patients who do not wish to be notified of the fMRI examination results.
  • 6) Patients judged ineligible to participate in the study by the attending psychiatrist.
  • 7) Patients taking paroxetine.

研究者

发起方
Matsumoto Toshihiko

相似试验